⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Journal for ImmunoTherapy of CancerOpen Access

Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial

Yandong He Xuhong Huang Xiaoxia Li Hongwei Liu Min Liu Jun-jia Tao Yuanzhou Shan Hafiz Khuram Raza Yanqiu Liu Wenting Zhong Xue-ping Cao Yuanyuan Yang Ruimei Li Xian-Long Fang Kang-jian Zhang Rong Zhang Feng Liu

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the safety and preliminary efficacy of YSCH-01 (Recombinant L-IFN adenovirus) in subjects with advanced solid tumors.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

He et al. (2024) studied this question.

synapsesocial.com/papers/68e6c03bb6db64358763fb8b https://doi.org/10.1136/jitc-2024-008999

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1An investigator-initiated trial to evaluate safety and tolerability of YSCH-01 in patients with recurrent glioblastoma.2024 · 1 citations
2Phase 1/2 study of YL201, an anti-B7H3 antibody–drug conjugate (ADC), in patients with relapsed or refractory (R/R) Ewing sarcoma and chondrosarcoma.Early-Phase Clinical Trial · 2026 · 2 citations
3SYS6010 combined with SYH2051 in advanced solid tumors: Results from a phase Ib/II trial.Early-Phase Clinical Trial · 2026
4A phase II clinical trial of intravesical YH01 for BCG-unresponsive high-risk non–muscle-invasive bladder cancer (NMIBC).Human Clinical Trial · 2026
5First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCCEarly-Phase Clinical Trial · 2026 · 4 citations

An open-label phase I study to evaluate the safety, tolerability and preliminary efficacy of YY001 in patients with advanced solid tumors.2024
First-in-human study of SYS6043, a novel B7-H3–targeting antibody-drug conjugate, in patients with advanced pan-tumor malignancies.2026
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors2026
Hormone therapy potentiates chemoimmunotherapy by inducing SUMOylation-mediated immunogenic cell deathJournal for ImmunoTherapy of Cancer · 2026
Propionate promotes CD8 + T-cell infiltration and enhances immunotherapy efficacy in colorectal cancerJournal for ImmunoTherapy of Cancer · 2026

More from Journal for ImmunoTherapy of Cancer

More from Shanghai Jiao Tong University

More from Shanghai Sixth People's Hospital

More from YangPu Geriatric Hospital